Provide your eligible patients with a free 30-day supply of SINGULAIR using this simple, printable eVoucher.
Limitations apply. Please see Terms and Conditions for details.
The NIH guidelines emphasize the importance of asthma control and introduce various approaches for monitoring asthma. View some key points and helpful resources for your practice.
In a retrospective study in Canada, asthma hospitalizations for children aged 5 to 15 years were shown to be highest in September.
Learn more.Asthma Therapy Assessment Questionnaire (ATAQ)
The NIH guidelines recommend scientifically validated self-assessment tools such as ATAQ to help monitor asthma control.
View more than a dozen asthma presentations— live and interactive, or archived.
Sign up to receive more information about SINGULAIR.
Request complimentary samples of SINGULAIR, register for online seminars, and more.
Merck offers special programs to make SINGULAIR more affordable for your patients.
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients aged 12 months and older and for prevention of exercise-induced bronchoconstriction (EIB) in patients aged 15 years and older.
For prevention of EIB, a single dose of SINGULAIR should be taken at least 2 hours before exercise. An additional dose of SINGULAIR should not be taken within 24 hours of a previous dose.
Patients already taking 1 tablet daily for another indication should not take an additional dose to prevent EIB.
SELECTED SAFETY INFORMATION
- SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
- Neuropsychiatric events have been reported in patients taking SINGULAIR. These events included agitation, aggressive behavior or hostility, anxiousness, depression, dream abnormalities, hallucinations, insomnia, irritability, restlessness, somnambulism, suicidal thinking and behavior (including suicide), and tremor. The clinical details of some postmarketing reports appear consistent with a drug-induced effect. Patients should be advised to report any neuropsychiatric events.
- Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
- Safety and effectiveness of SINGULAIR in patients younger than 12 months with asthma have not been established.
Before prescribing SINGULAIR, please read the Prescribing Information.
For general information and other services for physicians
SINGULAIR, Merck OnCall, and MerckServices are registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
MerckProductServices is a trademark of Merck & Co., Inc.
PRIVACY POLICY